Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 6, 2021updated 07 Jan 2022 6:39am

I-Mab doses first two subjects in solid tumour treatment trial in US

The trial will assess the clinical activities of uliledlimab and atezolizumab to treat advanced or metastatic solid tumours. 

I-Mab has dosed the first two subjects in a Phase II dose expansion clinical trial of its humanised CD73 antibody, uliledlimab, plus atezolizumab (Tecentriq) to treat individuals with ovarian cancer and various other advanced or metastatic solid tumours in the US.

Uliledlimab attaches to a unique epitope and fully hinders inhibits CD73, overturning the adenosine-facilitated immunosuppression in the tumour microenvironment and hindering its growth.

The multicentre, open-label trial in the US will analyse the clinical activities of uliledlimab plus atezolizumab, as well as possible biomarkers in subjects with certain advanced or metastatic solid tumours.

A dose-expansion arm enrolling ovarian cancer patients who are resistant to platinum treatment, and a biomarker-driven ‘basket’ arm of subjects with head and neck squamous cell carcinoma, gastrointestinal cancer, non-small cell lung cancer, triple-negative breast cancer or PD-L1 expressing ovarian cancer will be part of the trial.

In addition to the US trial, uliledlimab is being analysed in a trial in China on a separate targeted group of patients.

The clinical results from both the geographies will be used to expand the worldwide development to initiate a pivotal trial in people with specific solid tumour types.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

In Phase I trial, uliledlimab plus atezolizumab was found to have encouraging and good clinical activity in advanced tumour patients.

The recommended dose for the Phase II trial was selected based on data from the Phase I trial.

I-Mab CEO Dr Joan Shen said: “Uliledlimab has unique pharmacological properties, which position it as the next-generation immuno-oncology agent.

“We hope the data from this study will accelerate the clinical development towards registration and to address the needs of patients with immune checkpoint resistance.”

The company is also carrying out a Phase II cohort expansion trial of uliledlimab plus toripalimab (TUOYI) in China enrolling individuals with advanced or metastatic cancers and are refractory to or not tolerant of currently offered treatments.

In May, I-Mab dosed the first patient in a Phase II abbreviated combination clinical trial of lemzoparlimab plus azacitidine in people with recently diagnosed acute myeloid leukaemia or myelodysplastic syndrome in China.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU